

NNDSS Modernization Initiative Technical Assistance Coordination Team Update

November 7, 2014

Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for November 7, 2014. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and will be sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

Message Mapping Guide Development Updates

- **Message Mapping Guide (MMG) Status Updates:**

- In response to the document “Best Practices Recommendations for Unknown Values in Case Notification Messages” shared with CDC program subject matter experts (SMEs), the CDC Division of Health Informatics and Surveillance (DHIS) Message and Vocabulary (M&V) Team has received requests to add indicator elements for specific data elements from SMEs in the CDC National Center for Immunization and Respiratory Diseases (NCIRD) and the CDC STD program. CDC is developing plans for next steps in the process of soliciting feedback about the recommendations for handling unknown values in case notification messages.
- **Mumps and Pertussis MMGs ([Stage I–Draft Phase](#)):**
 - The MMG Development Team has received requests from NCIRD to add indicator data elements (to distinguish unknown and missing responses) for selected date/numeric data elements.
 - After the indicator data elements have been included in the MMGs, the MMG Development Team will post the MMGs for a second external review period of 6 weeks.
 - During the external review period, the CDC Platform-Message Validation and Processing System (CDCP-MVPS) team will work to develop draft internal data provisioning requirements.
- **Congenital Syphilis and STD MMGs ([Stage II–Reconciled Draft Phase](#))**
 - The MMG Development Team has received requests from the CDC STD program to add indicator data elements for selected date/numeric data elements and one expanded value set for a coded data element.
 - The Congenital Syphilis MMG requires changes to make the infant the focus of the case investigation rather than the mother and to address the addition of indicator elements.
 - The MMG Development Team will revise and post the STD and Congenital Syphilis MMGs as soon as possible as [Stage III—Pilot Test-ready Draft Phase](#) versions of the MMGs, along with their artifacts. As the MMGs are updated, the MMG Development Team will provide them to the CDCP-MVPS team for implementation purposes.

- **Generic v2 and Hepatitis MMGs** ([Stage III—Pilot Test-ready Draft Phase](#))
 - Some of the CDC program requests for indicator data elements will affect the Generic v2 MMG but NOT the Hepatitis MMG.
 - The MMG Development Team has revised the Generic v2 test scenarios due to minor inconsistencies and will create new test messages from the revised test scenarios.
 - The MMG Development Team also is revising the Hepatitis test scenarios and test messages.
 - The MMG Development Team will post updated versions of the Generic v2 and Hepatitis artifacts to the Draft MMG Web site as soon as possible.
- No guides are in [Stage IV—Final MMG Phase](#) at this time.
- Jurisdictions selected for pilot testing of the test-ready versions of MMGs should wait until they are contacted by the NMI Technical Assistance Coordination Team before using the test-ready MMGs and submitting test messages to CDC. All other jurisdictions should not plan to submit data to CDC until the final MMGs have been posted to the Public Health Information Network (PHIN) Web site.
- For more information about MMG development, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.

CDC Platform-Message Validation and Processing System Updates

- The CDCP-MVPS team will continue to work with CSTE and APhL to facilitate beta testing with Michigan, which is currently in progress.
 - Beta testing is designed to identify any gaps that can be remediated before testing with the other pilot jurisdictions is initiated.
 - Pilot testing will expand to other jurisdictions post-beta testing.
 - As part of the beta with Michigan, the CDCP-MVPS team will document best practices, which will help determine an optimal transition approach for future pilot jurisdictions.
- The CDCP-MVPS team has developed and provided data provisioning requirements to AgileX for Generic v2, Hepatitis, STD, and Congenital Syphilis. Data provisioning documents are developed by disease condition. Following is the status of specific requirements provided to AgileX:
 - Generic v2: The CDCP-MVPS team received the software build for Generic v2 from AgileX.
 - Hepatitis: The CDCP-MVPS team received the software build for Hepatitis from AgileX.
 - STD:
 - The CDCP-MVPS team received the software build for STD from AgileX.
 - The NMI TA Coordination Team will work with Michigan to develop to the STD MMG when the guide reaches [Stage III—Pilot Test-ready Draft Phase](#). As a result, testing of STD is targeted for December 2014.
 - Congenital Syphilis:
 - Discussions among the CDCP-MVPS team, the MMG Development Team, and AgileX to clarify requirements are ongoing and extensive. The design of the Congenital Syphilis MMG may be altered to better align with HL7 approaches toward mother/child relationship and who is actually the patient, which will require processing and provisioning adjustments.
 - The CDCP-MVPS team is defining a new date for the software build to be provided by AgileX due to changes in the Congenital Syphilis MMG that have not yet been finalized.
 - Due to changes in the Congenital Syphilis MMG, testing of these messages is targeted for early 2015.

- Mumps and Pertussis:
 - The CDCP-MVPS team will not define dates for CDCP-MVPS activities related to Mumps and Pertussis until those MMGs are finalized and posted for external partner review.
 - The MMGs for Mumps and Pertussis have been redeveloped and will go through external partner review for a second time.
 - The CDCP-MVPS team will then develop technical requirements and support software development.
- For more information about the CDCP-MVPS, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.

Technical Assistance Updates

- NMI Technical Assistance Coordination Team representatives from APHL continue to work virtually with Michigan to complete the remaining steps toward building test messages for Hepatitis.
 - The team and Michigan have targeted mid-November 2014 to begin end-to-end validation for Hepatitis test messages.
 - Michigan has successfully configured and tested their PHIN-Messaging System (PHIN-MS) staging route, which will be used to send test messages to the CDCP-MVPS user acceptance testing environment.
- The NMI Technical Assistance Coordination Team continues to hold initial calls with pilot sites, prioritizing states that will be working on Hepatitis messaging. APHL expects to be in touch soon with those pilot states that APHL has not been able to contact yet.
- For more information about Technical Assistance:
 - Please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.
 - For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, contractor to APHL, at lcarlton@TSJG.com.
 - For non-pilot jurisdictions: If you have questions or would like to request TA for MMG implementation through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

Best,
Members of the NMI TA Coordination Team